Prof. Dr. Katja Schenke-Layland
is the Director of the NMI Natural and Medical Sciences Institute in Reutlingen, the CEO of the NMI-TT GmbH, Professor of Medical Technologies and Regenerative Medicine at the Medical Faculty of the University Tübingen (MFT), and the Study Dean of Medical Technologies at the University of Tübingen.
More Information: Schenke-Layland Lab
- 2018 - today
- Direktorin, NMI Natural and Medical Sciences Institut at the University Tübingen in Reutlingen
- 2018 - today
- Co-Editor-in-Chief, Tissue Engineering, Part B (Mary Ann Liebert)
- 2011 - today
- Full Professor (W3), Eberhard Karls University of Tübingen (EKUT), Institute of Biomedical Engineering, Department of Medical Technology and Regenerative Medicine in Tübingen
- 2012 - today
- Executive Editor, Advanced Drug Delivery Reviews (ADDR) (Elsevier)
- 2018 - today
- Project Scientist, University of California Los Angeles (UCLA), Dept. of Medicine/ Cardiology, Cardiovascular Research Laboratories (CVRL) in Los Angeles, USA
- 2013 - 2018
- Adjunct Associate Professor, UCLA, Dept. of Medicine/ Cardiology in Los Angeles, USA
- 2016 - 2017
- Director (interim., managing), Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) in Stuttgart, Germany
- 2013 - 2017
- Head of Department, Fraunhofer IGB, Department of Cell and Tissue Engineering in Stuttgart, Germany
- 2010 - 2013
- Visiting Associate Professor, UCLA, Dept. of Medicine/ Cardiology in Los Angeles, USA
- 2010 - 2014
- ATTRACT-Group Leader, Fraunhofer IGB, Stuttgart, Deutschland
- 2010 - 2013
- Deputy Head of Department, Fraunhofer IGB, Dept. of Cell and Tissue Engineering in Stuttgart, Germany
- 2008 - 2009
- Assistant Research Professor, UCLA, Dept. of Medicine/ Cardiology in Los Angeles, USA
- 2005 - 2008
- Postdoctoral Research Fellow, UCLA, Cardiovascular Research Laboratories in Los Angeles, USA
- 2004 - 2005
- Postdoctoral Research Fellow, Children's Hospital Los Angeles, Saban Research Institute in Los Angeles, USA
- 2001 - 2004
- Promotion in Biologie/ Cardiovascular Tissue Engineering, Friedrich-Schiller-Universität (FSU) Jena
- 1995 - 2000
- M.Sc. in Biology, Sociology, Psychology, Friedrich-Schiller-University (FSU) Jena
She is currently the Co-Editor-In-Chief of Tissue Engineering Part B (Mary Ann Liebert) and Executive Editor of Advanced Drug Delivery Reviews (Elsevier), as well as on several editorial boards such as Matrix Biology (Elsevier), Current Opinion in Biomedical Engineering (Elsevier), and Journal of 3D Printing in Medicine (Future Medicine). She is a fellow/ board member of the German National Academy of Science and Engineering (acatech), German Central Ethics Committee for Stem Cell Research (ZES), International and German Societies of Matrix Biology, and the European Alliance for Medical and Biological Engineering and Science (EAMBES).
Professor Dr. Katja Schenke-Layland studied biology, sociology and psychology at the Friedrich Schiller University in Jena. There she received her PhD in Biology in Cardiovascular Tissue Engineering in 2004. She received a postdoctoral research fellowship at the Saban Research Institute of the Children's Hospital at the University of Southern California in Los Angeles (2004-2005) and following this she received another postdoctoral research fellowship at the David Geffen School of Medicine at the University of California Los Angeles UCLA, USA (2005-2008). In 2008, she was appointed Assistant Research Professor in the Department of Medicine/Cardiology at UCLA and is currently an Adjunct Associate Professor. In January 2010, she became group leader of the Fraunhofer Attract Group at the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Department of Cell and Tissue Engineering in Stuttgart, Germany, and later assumed the position of department head. From 2016 to 2017, she was acting institute director of the Fraunhofer IGB before then joining the NMI in 2018.
Publications (max. 5)
- Calvanese V, Capellera-Garcia S, Ma F, Fares I, Liebscher S, Ng ES, Ekstrand S, Aguadé-Gorgorió J, Vavilina A, Lefaudeux D, Nadel B, Li JY, Wang Y, Lee LK, Ardehali R, Iruela-Arispe ML, Pellegrini M, Stanley EG, Elefanty AG, Schenke-Layland K, Mikkola HKA. Mapping human haematopoietic stem cells from haemogenic endothelium to birth. Nature 604: 534-540 (2022) https://doi.org/10.1038/s41586-022-04571-x
- Feuerer N, Marzi J, Brauchle EM, Carvajal Berrio DA, Billing F, Weiss M, Jakobi M, Schneiderhan-Marra N, Shipp C, Schenke-Layland K. Lipidome profiling with Raman microspectroscopy identifies macrophage response to surface topographies of implant materials. Proc Natl Acad Sci USA 118(52): e2113694118 (2021) https://doi.org/10.1073/pnas.2113694118
- Zbinden A*, Layland SL*, Urbanczyk M, Carvajal Berrio DA, Marzi J, Zauner M, Hammerschmidt A, Brauchle EM, Sudrow K, Fink S, Templin M, Liebscher S, Klein G, Deb A, Duffy GP, Crooks GM, Eble JA, Mikkola HKA, Nsair A, Seifert M, Schenke-Layland K. Nidogen-1 mitigates ischemia and promotes tissue survival and regeneration. Adv Sci (Weinh) 8(4): 2002500 (2021) https://doi.org/10.1002/advs.202002500
- Shen N, Knopf A, Westendorf C, Kraushaar U, Riedl J, Bauer H, Pöschel S, Layland SL, Monika Holeiter M, Knolle S, Brauchle E, Nsair A, Hinderer S, Schenke-Layland K. Steps towards maturation of embryonic stem cell-derived cardiomyocytes by defined physical signals. Stem Cell Reports 9(1): 122-135 (2017) https://doi.org/10.1016/j.stemcr.2017.04.021
- Schenke-Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan-Hagvall S, Gekas C, Zhang R, Goldhaber JI, Mikkola HK, Plath K, MacLellan WR. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 26(6): 1537-1546 (2008) https://doi.org/10.1634/stemcells.2008-0033
ORCID ID: 0000-0001-8066-5157
NMI Natural and Medical Sciences Institute
at the University of Tübingen
Markwiesenstraße 55, 72770 Reutlingen
Tel.: +49 7121 51530-0
Mail: info@nmi.de
Follow us now
